Squarepoint’s PMV Pharmaceuticals PMVP Stock Holding History
Bought
Maintained
Sold
Other funds holding PMVP
BCM
TCM
SCM
ACH
EC
EP
VCM
Squarepoint's PMVP Position: Q1 2026 in Review
Squarepoint increased its PMV Pharmaceuticals (PMVP) stake by 3.3% in Q1 2026, buying an estimated $1.12K and bringing the position to 27,381 shares worth $34K. The position accounts for ﹤0.01% of the portfolio, ranked #4164.
Squarepoint first reported a position in PMVP in Q3 2020 and has held it in 16 quarters since. The position peaked at $1.22M in Q1 2023. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.
- Squarepoint held 27,381 shares of PMV Pharmaceuticals worth $34K as of Q1 2026.
- Squarepoint bought 879 PMV Pharmaceuticals shares in Q1 2026, an estimated $1.12K.
- PMV Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4164 holding.
- Squarepoint first reported a position in PMV Pharmaceuticals in Q3 2020 and has held it in 16 quarters since.
- Squarepoint's PMV Pharmaceuticals position peaked at $1.22M in Q1 2023.
- 69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.